Cover Image
市場調查報告書

X-BODY BioSciences, Inc.的產品平台分析

X-BODY BioSciences, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321338
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
X-BODY BioSciences, Inc.的產品平台分析 X-BODY BioSciences, Inc. - Product Pipeline Review - 2014
出版日期: 2014年12月15日 內容資訊: 英文 30 Pages
簡介

X-BODY BioSciences, Inc.是總公司在美國的生物科技企業,進行緩和非肺部小細胞癌中幹細胞的浸潤及擴散的激酶途徑為目標的藥物開發等。

本報告提供X-BODY BioSciences, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

X-BODY BioSciences, Inc. 的基本資料

  • X-BODY BioSciences, Inc. 概要
  • 主要資訊
  • 企業資料

X-BODY BioSciences, Inc. :R&D概要

  • 主要的治療範圍

X-BODY BioSciences, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

X-BODY BioSciences, Inc. :開發中產品概況

  • 初期階段有的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

X-BODY BioSciences, Inc. :藥物簡介

  • hMABs For Cancer
  • XB-2202
  • Monoclonal Antibodies to Target GCGR for Diabetes and Obesity
  • Monoclonal Antibody for Autoimmune and Inflammation
  • Monoclonal Antibody for Cancer
  • Monoclonal Antibody to Activate Class B GPCR for Diabetes and Obesity
  • Monoclonal Antibody to Antagonize CXCR4 for Cancer
  • Monoclonal Antibody to Inhibit M3 for Irritable Bowel Syndrome
  • Monoclonal Antibody to Inhibit NaV 1.7 for Pain
  • Monoclonal Antibody to Inhibit TRPA1 for Pain

X-BODY BioSciences, Inc. :開發平台分析

  • 各標的
  • 各分子類型
  • 各作用機制

X-BODY BioSciences, Inc. :最新的開發平台資訊

X-BODY BioSciences, Inc. :開發休止的計劃

X-BODY BioSciences, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06673CDB

Summary

Global Markets Direct's, 'X-BODY BioSciences, Inc. - Product Pipeline Review - 2014', provides an overview of the X-BODY BioSciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of X-BODY BioSciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of X-BODY BioSciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of X-BODY BioSciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the X-BODY BioSciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate X-BODY BioSciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of X-BODY BioSciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the X-BODY BioSciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of X-BODY BioSciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of X-BODY BioSciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of X-BODY BioSciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • X-BODY BioSciences, Inc. Snapshot
    • X-BODY BioSciences, Inc. Overview
    • Key Information
    • Key Facts
  • X-BODY BioSciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • X-BODY BioSciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • X-BODY BioSciences, Inc. - Pipeline Products Glance
    • X-BODY BioSciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • X-BODY BioSciences, Inc. - Drug Profiles
    • hMABs For Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XB-2202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Target GCGR for Diabetes and Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Autoimmune and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Activate Class B GPCR for Diabetes and Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CXCR4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit M3 for Irritable Bowel Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit NaV 1.7 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TRPA1 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • X-BODY BioSciences, Inc. - Pipeline Analysis
    • X-BODY BioSciences, Inc. - Pipeline Products by Target
    • X-BODY BioSciences, Inc. - Pipeline Products by Molecule Type
    • X-BODY BioSciences, Inc. - Pipeline Products by Mechanism of Action
  • X-BODY BioSciences, Inc. - Recent Pipeline Updates
  • X-BODY BioSciences, Inc. - Dormant Projects
  • X-BODY BioSciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • X-BODY BioSciences, Inc., Key Information
  • X-BODY BioSciences, Inc., Key Facts
  • X-BODY BioSciences, Inc. - Pipeline by Indication, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Stage of Development, 2014
  • X-BODY BioSciences, Inc. - Monotherapy Products in Pipeline, 2014
  • X-BODY BioSciences, Inc. - Preclinical, 2014
  • X-BODY BioSciences, Inc. - Discovery, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Target, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Molecule Type, 2014
  • X-BODY BioSciences, Inc. - Pipeline Products by Mechanism of Action, 2014
  • X-BODY BioSciences, Inc. - Recent Pipeline Updates, 2014
  • X-BODY BioSciences, Inc. - Dormant Developmental Projects,2014

List of Figures

  • X-BODY BioSciences, Inc. - Pipeline by Top 10 Indication, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Stage of Development, 2014
  • X-BODY BioSciences, Inc. - Monotherapy Products in Pipeline, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Top 10 Target, 2014
  • X-BODY BioSciences, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • X-BODY BioSciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top